ClinicalTrials.gg
RecruitingNCT06102109YAMPOINTUpdated Oct 26, 2023

Long-term Results of Two Surgical Methods for Scleral IOL Implantation and Fixation in Eyes Without Capsular Support: Yamane- Versus 4-flanged Technique

An interventional study of Pars plana vitrectomy and IOL explantation in Lens Luxation, IOL Subluxation and IOL Opacification, sponsored by Medical University of Vienna. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Medical University of Vienna · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This study is a comparison of the surgical techniques and postoperative outcome between the two intrascleral IOL fixation techniques: Yamane technique versus the 4-flanged technique.

The main objectives are postoperative lens tilt, duration of surgery, intra- and postoperative complication rates and scleral integrity around the flanges.

02

Conditions studied

  • Lens Luxation
  • IOL Subluxation
  • IOL Opacification
  • Aphakia - No Lens Capsule

Keywords

  • Scleral fixated IOL
  • Yamane
  • 4 flanged technique
03

In context

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Necessity for IOL (re)fixation in the absence of capsular support
  • willing to give and follow-up the duration of study

Exclusion criteria

Exclusion Criteria:

  • Anatomical or other for suture less IOL fixation, such as presence of a trabeculectomy bleb or scleromalacia
  • active inflammatory diseases of the eye
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Yamane Arm

    Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera.

    Procedure: Pars plana vitrectomy · Procedure: IOL explantation · Procedure: Scleral IOL fixation Yamane Technique

  • Active comparator
    "4-flanged" Arm

    Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physiol Micropure 123) gets fixated in the sclera using 6.0 polypropylene suture

    Procedure: Pars plana vitrectomy · Procedure: IOL explantation · Procedure: Scleral IOL fixation "4-flanged" Technique

Interventions

  • ProcedurePars plana vitrectomy

    25gauge pars plana vitrectomy: to remove the vitreous if present

  • ProcedureIOL explantation

    Removing if present a subluxated IOL from the anterior chamber or the vitreous cavity

  • ProcedureScleral IOL fixation Yamane Technique

    Scleral IOL fixation using the Yamane technique. A 3 piece IOL (Kowa Avansee Preset) gets fixated in the sclera using only its haptics, which are externalised 2.5mm behind the blue line. The haptic ends are flanged using a thermo cautery to prevent slipping back in.

  • ProcedureScleral IOL fixation "4-flanged" Technique

    Scleral IOL fixation using the 4 flanged technique. A 4 loop haptic IOL (Physical Micropure 123) gets fixated in the sclera using one 6.0 polypropylene suture per 2 haptic loops, which are put trough the loops in a W shape. The suture ends are externalised 2.5mm behind the blue line and its ends are flanged using a thermo cautery to prevent slipping back in.

06

What researchers measure

Primary outcomes

  1. IOL tilt

    The postoperative intra ocular lens tilt in degree measured by an anterior segment optical coherence tomography device (Casia 2, Tommy, Japan)

    Time frame: 3 years

  2. IOL decentration

    The postoperative intra ocular lens decentration in millimetres measured by an anterior segment optical coherence tomography device (Casia 2, Tommy, Japan)

    Time frame: 3 years

Secondary outcomes

  1. Best corrected visual outcome

    The achieved best corrected visual (in Snellen) outcome after Intraocular lens implantation

    Time frame: 12 weeks

  2. Flange erosion and intrusion

    Risks of flange erosion trough the conjuctiva or intrusion through the sclera over the investigated time period

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06102109
Responsible party
Claudette Abela-Formanek (Univ. Prof. Dr., Medical University of Vienna) — Principal investigator
First posted
Oct 26, 2023
Start date
Sep 19, 2023
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 26, 2023

Study contacts

Markus Schranz, Md
Contact
markus.schranz@meduniwien.ac.at
+4314040079690

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion